OOIR: Observatory of International Research

Papers

(The TQCC of Best Practice & Research Clinical Haematology is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-07-01 to 2024-07-01.)

Article	Citations
Germline predisposition in myeloid neoplasms: Unique genetic and clinical features of GATA2 deficiency and SAMD9/SAMD9L syndromes	70
Molecular markers in ALL: Clinical implications	32
COVID-19 disease and immune dysregulation	30
Immunologic effects on the haematopoietic stem cell in marrow failure	23
The promise of macrophage directed checkpoint inhibitors in myeloid malignancies	20
CD33 directed bispecific antibodies in acute myeloid leukemia	18
Perspectives on current survival and new developments in AML	17
Immune checkpoint inhibitors in acute myeloid leukemia	17
Acute myeloid leukemia and artificial intelligence, algorithms and new scores	17
COVID-19 and antiphospholipid antibodies	16
Treatment of telomeropathies	16
Mechanisms for resistance in AML insights into molecular pathways mediating resistance to venetoclax	14
TCR gene-engineered cell therapy for solid tumors	14
CD123 bi-specific antibodies in development in AML: What do we know so far?	13
Distinguishing constitutional from acquired bone marrow failure in the hematology clinic	13
Congenital amegakaryocytic thrombocytopenia – Not a single disease	12
Biology and clinical management of hypoplastic MDS: MDS as a bone marrow failure syndrome	12
COVID-19 and HSCT (Hematopoietic stem cell transplant)	12
New targets for CAR T therapy in hematologic malignancies	11
Blood coagulation and cancer genes	10
Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?	10
Controversies in the recent (2016) World Health Organization classification of acute myeloid leukemia	10
Have any strategies in Ph-like ALL been shown to be effective?	10
Effectiveness of allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia	10
Somatic mosaicism in inherited bone marrow failure syndromes	10

Redefining the biological basis of lineage-ambiguous leukemia through genomics: BCL11B deregulation in acute leukemias of ambiguous lineage	10
Mechanisms of thrombosis in pancreatic ductal adenocarcinoma	9
Toxicities associated with adoptive cellular therapies	9
Thrombosis and bleeding in hematological malignancy	9
Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: What have we learned so far and where are we heading?	8
GATA2 and marrow failure	8
Diagnosis and management of lymphoblastic lymphoma in children, adolescents and young adults	8
Clinical experience of CAR T cells for multiple myeloma	7
Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults	7
Overcoming graft failure after haploidentical transplantation: Is this a possibility?	7
WGS and WTS in leukaemia: A tool for diagnostics?	7
Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents	7
Molecular genetics of MDS/MPN overlap syndromes	7
Cytogenetics in the genomic era	7
Has Ph-like ALL Superseded Ph+ ALL as the Least Favorable Subtype?	6
Clonal hematopoiesis and bone marrow failure syndromes	6
CML - Not only BCR-ABL1 matters	6
Vaccine-induced immune thrombotic thrombocytopenia	6
Antibody based therapy in relapsed acute lymphoblastic leukemia	6
Diagnosis and management of Hodgkin lymphoma in children, adolescents, and young adults	6
Dysregulation of Protein S in COVID-19	5
Important factors improving outcome of young adults with acute lymphoblastic leukemia (ALL)	5
Challenges in anticoagulation for patients with brain tumors	5
Coagulopathy in COVID-19 and anticoagulation clinical trials	5
Spliceosomal factor mutations and mis-splicing in MDS	5
SARS-CoV-2 primary and breakthrough infections in patients with cancer: Implications for patient care	5
Can venetoclax-based therapy replace 7+3 induction in fit older adults with AML?	5
Advances in CAR design	5
Diagnosis and management of rare paediatric Non-Hodgkin lymphoma	5
Myeloproliferative neoplasms in adolescents and young adults	5
Bone marrow transplantation for acquired aplastic anemia: What's new	5
Measurable residual disease in acute lymphoblastic leukemia: How low is low enough?	5
Accelerated and blast phase myeloproliferative neoplasms	5
Myeloid neoplasms with germline predisposition: Practical considerations and complications in the search for new susceptibility loci	5
Marrow failure and aging: The role of “Inflammaging”	5